| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alexandre Seillie. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neuroscience letters. vol 759. 2021-08-06. PMID:34146641. |
the endocannabinoid system as a therapeutic target for schizophrenia: failures and potentials. |
2021-08-06 |
2023-08-13 |
Not clear |
| Alexandre Seillie. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neuroscience letters. vol 759. 2021-08-06. PMID:34146641. |
in the second part, the author highlights the most promising strategies, as well as the most interesting directions one could follow, in the emerging field of cannabinoid therapies for schizophrenia. |
2021-08-06 |
2023-08-13 |
Not clear |
| Judit García-González, Bruno de Quadros, William Havelange, Alistair J Brock, Caroline H Brenna. Behavioral Effects of Developmental Exposure to JWH-018 in Wild-Type and Disrupted in Schizophrenia 1 ( Biomolecules. vol 11. issue 2. 2021-07-23. PMID:33669793. |
behavioral effects of developmental exposure to jwh-018 in wild-type and disrupted in schizophrenia 1 ( synthetic cannabinoids can cause acute adverse psychological effects, but the potential impact when exposure happens before birth is unknown. |
2021-07-23 |
2023-08-13 |
Not clear |
| Kurt Leroy Hoffma. From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia. Frontiers in psychiatry. vol 12. 2021-07-23. PMID:34290632. |
from the clinic to the laboratory, and back again: investigations on cannabinoids and endocannabinoid system modulators for treating schizophrenia. |
2021-07-23 |
2023-08-13 |
Not clear |
| Kurt Leroy Hoffma. From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia. Frontiers in psychiatry. vol 12. 2021-07-23. PMID:34290632. |
the present mini-review focuses on animal models of schizophrenia that have explored the effects of cannabidiol (cbd; a non-psychoactive component of cannabis) or the pharmacological manipulation of the endocannabinoid system on behavioral and cognitive outcome measures. |
2021-07-23 |
2023-08-13 |
Not clear |
| Oualid Abboussi, Zineb Ibn Lahmar Andaloussi, Ajonijebu Duyilemi Chris, Khalid Taghzout. Chronic Exposure to WIN55,212-2 During Adolescence Alters Prefrontal Dopamine Turnover and Induces Sensorimotor Deficits in Adult Rats. Neurotoxicity research. vol 38. issue 3. 2021-07-09. PMID:32757167. |
several lines of evidence suggest that chronic exposure to cannabinoids during adolescence may increase the risk of schizophrenia. |
2021-07-09 |
2023-08-13 |
rat |
| Rodrigo Ferretjans, Renan P de Souza, Bruna Panizzutti, Pâmela Ferrari, Lucas Mantovani, Salvina M de Campos-Carli, Rafael R Santos, Fernanda C Guimarães, Antonio L Teixeira, Clarissa S Gama, João V Salgad. Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2021-06-30. PMID:34190825. |
to test the hypothesis that genetic variations of cannabinoid receptors contribute to the pathophysiology of cognitive deficits in schizophrenia. |
2021-06-30 |
2023-08-13 |
Not clear |
| Francisco Arias Horcajadas, José Ramón Dávila Píriz, Alba Parra González, Sergio Sánchez Romero, Eva Sánchez-Morla, Israel Ampuero Sánchez, José Antonio Ramos Atanc. Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population. Adicciones. vol 0. issue 0. 2021-06-25. PMID:34171108. |
the endocannabinoid system has been associated with various psychiatric disorders, such as schizophrenia or addictive disorders. |
2021-06-25 |
2023-08-13 |
human |
| Francisco Arias Horcajadas, José Ramón Dávila Píriz, Alba Parra González, Sergio Sánchez Romero, Eva Sánchez-Morla, Israel Ampuero Sánchez, José Antonio Ramos Atanc. Cannabinoid receptor type 2 gene is associated with comorbidity of schizophrenia and cannabis dependence and fatty acid amide hydrolase gene is associated with cannabis dependence in the Spanish population. Adicciones. vol 0. issue 0. 2021-06-25. PMID:34171108. |
we analysed different cannabinoid gene polimorphisms from non-substance using patients diagnosed with schizophrenia (n = 379), schizophrenic patients with cannabis use disorders (n = 124), cannabis users who did not have psychoses (n = 71), and 316 controls from various spanish hospitals and health centres. |
2021-06-25 |
2023-08-13 |
human |
| Erica Zamberletti, Tiziana Rubin. Impact of Endocannabinoid System Manipulation on Neurodevelopmental Processes Relevant to Schizophrenia. Biological psychiatry. Cognitive neuroscience and neuroimaging. vol 6. issue 6. 2021-06-24. PMID:32855107. |
impact of endocannabinoid system manipulation on neurodevelopmental processes relevant to schizophrenia. |
2021-06-24 |
2023-08-13 |
Not clear |
| Erica Zamberletti, Tiziana Rubin. Impact of Endocannabinoid System Manipulation on Neurodevelopmental Processes Relevant to Schizophrenia. Biological psychiatry. Cognitive neuroscience and neuroimaging. vol 6. issue 6. 2021-06-24. PMID:32855107. |
we review the most recent preclinical studies that evaluated the impact of endocannabinoid system modulation in the two sensitive developmental windows on neurodevelopmental processes that possess a specific relevance to schizophrenia. |
2021-06-24 |
2023-08-13 |
Not clear |
| Faith Borgan, Michelle Kokkinou, Oliver Howe. The Cannabinoid CB Biological psychiatry. Cognitive neuroscience and neuroimaging. vol 6. issue 6. 2021-06-24. PMID:33077399. |
the cannabinoid cb converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid cb |
2021-06-24 |
2023-08-13 |
Not clear |
| Zhaohong Qin, Li Zhang, Shelly A Cruz, Alexandre F R Stewart, Hsiao-Huei Che. Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 45. issue 11. 2021-06-23. PMID:32610340. |
cannabis use has been tied to schizophrenia-like symptoms, indicating that dysregulated endogenous cannabinoid signaling may be causally linked to schizophrenia. |
2021-06-23 |
2023-08-13 |
mouse |
| Ariel L Dunn, Patricia T Michie, Deborah M Hodgson, Lauren Harm. Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. Neuroscience and biobehavioral reviews. vol 116. 2021-06-21. PMID:32610181. |
adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: a review of the evidence from animal models. |
2021-06-21 |
2023-08-13 |
Not clear |
| Faith Borgan, Mattia Veronese, Tiago Reis Marques, David J Lythgoe, Oliver Howe. Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study. European archives of psychiatry and clinical neuroscience. vol 271. issue 4. 2021-05-27. PMID:32986150. |
cannabinoid 1 receptor and glutamatergic dysfunction have both been implicated in the pathophysiology of schizophrenia. |
2021-05-27 |
2023-08-13 |
human |
| Dan L McElroy, Andrew J Roebuck, Gavin A Scott, Quentin Greba, Sumanta Garai, Eileen M Denovan-Wright, Ganesh A Thakur, Robert B Laprairie, John G Howlan. Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology. vol 238. issue 4. 2021-03-30. PMID:33442771. |
given the known interactions between nmda receptors and type 1 cannabinoid receptors (cb1r), compounds that modulate cb1rs may have therapeutic potential for schizophrenia. |
2021-03-30 |
2023-08-13 |
Not clear |
| Jeremy J Watts, Maya R Jacobson, Nittha Lalang, Isabelle Boileau, Rachel F Tyndale, Michael Kiang, Ruth A Ross, Sylvain Houle, Alan A Wilson, Pablo Rusjan, Romina Mizrah. Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. Biological psychiatry. vol 88. issue 9. 2021-03-08. PMID:32387132. |
the endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia. |
2021-03-08 |
2023-08-13 |
Not clear |
| Mohini Ranganathan, Deepak Cyril D'Souz. Alterations in the Endocannabinoid System in Schizophrenia. Biological psychiatry. vol 88. issue 9. 2021-03-08. PMID:33032694. |
alterations in the endocannabinoid system in schizophrenia. |
2021-03-08 |
2023-08-13 |
Not clear |
| Lucas J A Durieux, Sara R J Gilissen, Lutgarde Arcken. Endocannabinoids and cortical plasticity: CB1R as a possible regulator of the excitation/inhibition balance in health and disease. The European journal of neuroscience. 2021-02-06. PMID:33427341. |
the endocannabinoid system has been linked to neurological disorders in which the excitation inhibition (e/i) balance in the neocortex is dysregulated, such as schizophrenia. |
2021-02-06 |
2023-08-13 |
Not clear |
| David W Volk, David A Lewi. Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia. JAMA psychiatry. vol 76. issue 9. 2021-01-04. PMID:31166594. |
insights into the pathophysiology of endocannabinoid signaling in schizophrenia. |
2021-01-04 |
2023-08-13 |
Not clear |